1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Crescent Energy said it expects about $40 million of total cash paid on its commodity derivative positions for the three months ended March 31, 2026. This reflects $101 million paid on settlements, partly offset by $61 million from derivative contracts acquired in the SilverBow and Vital mergers. The figures are preliminary and will be finalized in the company's Form 10-Q for the quarter.
Net cash paid on derivative settlements for Q1 2026: $101 million
Settlement of acquired derivative contracts from SilverBow and Vital mergers: $61 million
Total cash paid on commodity derivatives: about $40 million, excluding a $15.0 million Ridgemar earn-out settlement
Figures are preliminary; final amounts will appear in the Form 10-Q for the period ended March 31, 2026
WD-40 reported second-quarter fiscal 2026 results for the quarter ended February 28, 2026, with net sales up 11% to $161.7 million and non-GAAP adjusted diluted EPS up 14% to $1.50. GAAP diluted EPS fell 32% to $1.50 from $2.19, mainly because the prior-year quarter included an $11.9 million one-time tax benefit, and management reaffirmed its full-year fiscal 2026 guidance.
Total net sales were $161.7 million, up 11% from the prior-year quarter; on a constant currency basis, sales rose 4%.
Maintenance product sales rose 13% to $156.8 million, or 6% in constant currency.
GAAP diluted EPS was $1.50 versus $2.19; excluding the prior-year $11.9 million tax benefit, adjusted EPS rose 14%.
Management reaffirmed fiscal 2026 guidance, including diluted EPS of $5.75 to $6.15, and the company repurchased $8.0 million of shares in the quarter.
Buckle reported that net sales for the 5-week period ended April 4, 2026 rose 8.2% to $118.0 million, and comparable store net sales rose 7.0%. The company also appointed Scott A. Werth as Senior Vice President of Stores, effective March 31, 2026, to lead its sales team of more than 7,000 teammates across 42 states.
5-week fiscal month net sales increased 8.2% to $118.0 million from $109.1 million a year earlier
Comparable store net sales rose 7.0% for the 5-week period ended April 4, 2026
9-week year-to-date net sales increased 8.5% to $202.5 million from $186.6 million
Scott A. Werth, a Buckle employee since June 1989 and most recently Vice President of Sales and Strategy, was appointed SVP of Stores effective March 31, 2026
Simply Good Foods reported fiscal second-quarter 2026 net sales of $326.0 million, down from $359.7 million a year earlier, and a net loss of $159.7 million, driven by a $249.0 million non-cash impairment charge on the Atkins and OWYN brands. The company also updated its fiscal 2026 outlook, with net sales now expected at $1.31 to $1.35 billion and adjusted EBITDA at $217 to $225 million, and gave a third-quarter net sales range of $329 to $338 million.
Q2 net sales of $326.0 million fell 9.4%; Atkins declined 26.6% and OWYN 16.8%, while Quest grew 0.3%.
Q2 net loss of $159.7 million compared with net income of $36.7 million; adjusted diluted EPS was $0.45 versus $0.46.
Fiscal 2026 outlook: net sales $1.31 to $1.35 billion and adjusted EBITDA $217 to $225 million; gross margin expected to decline 300 to 350 basis points.
Q3 outlook: net sales of $329 to $338 million, down 14% to 11%, and adjusted EBITDA of $46 to $50 million.
Neogen reported fiscal third-quarter 2026 revenue of $211.2 million, down 4.4% from a year earlier, and a net loss of $17.0 million, or $(0.08) per share, compared with a $10.9 million loss a year earlier. The company raised its fiscal 2026 revenue guidance to $857 million to $860 million, kept Adjusted EBITDA guidance at about $175 million, and announced a $160.0 million sale of its Genomics business to Zoetis.
Q3 revenue was $211.2 million, down from $221.0 million; Animal Safety revenue fell 20.1% on third-party supplier issues
Net loss was $17.0 million, or $(0.08) per diluted share; Adjusted EPS was $0.09 versus $0.10 a year earlier
FY26 revenue guidance raised to $857 million to $860 million from $845 million to $855 million; Adjusted EBITDA guidance held at about $175 million
Genomics business to be sold to Zoetis Inc. for $160.0 million, expected to close by the end of fiscal 2Q27
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.